REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jan. 28, 2016--
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused
on improving the lives of patients by developing best-in-class medicines
that address major unmet medical needs, today announced the appointment
of Kimberly J. Manhard as Executive Vice President of Drug Development.
Ms. Manhard joins the Company today and will report to Barry D. Quart,
Pharm.D., Chief Executive Officer of Heron.
“Kimberly has played an important role at Heron since joining our Board
of Directors in January 2014, so we are delighted that she will be
joining the Company as a permanent member of our leadership team,”
commented Dr. Quart. “Kimberly brings to her role at Heron over 25 years
of drug development, regulatory affairs and pharmaceutical operations
experience, which will be invaluable to the Company as we move forward
with the development of our exciting pipeline of product candidates
targeting cancer or pain.”
Since 2008, Ms. Manhard has served as the Senior Vice President of
Regulatory Affairs and Development Operations at Ardea Biosciences,
Inc., a wholly-owned subsidiary of AstraZeneca PLC. In her role at
Ardea, Ms. Manhard was instrumental in the development and December 2015
regulatory approval of Zurampic® (lesinurad), by the U.S.
Food and Drug Administration (FDA) for the treatment of hyperuricemia
associated with gout. Ms. Manhard joined Ardea in 2006, overseeing
general corporate operations. Ardea Biosciences, Inc. was acquired by
AstraZeneca PLC for $1.26 billion in June 2012. Since its sale, Ms.
Manhard took on the additional roles of Ardea's Corporate Compliance
Officer and as a director of Ardea Biosciences Limited. Prior to her
tenure at Ardea, Ms. Manhard was President of her own consultancy firm,
Vice President of Regulatory Affairs for Exelixis, Inc., and held
multiple regulatory positions at Agouron Pharmaceuticals, Inc., a Pfizer
Inc. company, supporting the development and commercialization of
anticancer and antiviral products, including Viracept®
(nelfinavir). She was also previously with Bristol Myers Squibb Company
in regulatory affairs, responsible for oncology compounds, including
Taxol® (paclitaxel) and infectious disease compounds,
including Videx® (didanosine) and Zerit®
(stavudine).
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a biotechnology company focused on improving
the lives of patients by developing best-in-class medicines that address
major unmet medical needs. Heron is developing novel, patient-focused
solutions that apply its innovative science and technologies to
already-approved pharmacological agents for patients suffering from
cancer or pain. Heron’s goal is to build on therapeutics with well-known
pharmacology by improving their tolerability and efficacy as well as
broadening their potential field of use. For more information, visit www.herontx.com.
Forward Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, those associated with: whether the U.S. Food and
Drug Administration (FDA) completes its review within the anticipated
time period, whether the FDA approves the SUSTOL NDA as submitted or
supports as broad of a labeled indication for SUSTOL as requested, the
potential market opportunity for SUSTOL and expected timing of the
commercial launch, the progress in the research and development of
HTX-019, HTX-011 and our other programs, including the timing of
preclinical, clinical, and manufacturing activities, safety and efficacy
results from our studies that may not justify the pursuit of further
development of our product candidates, acceptance of SUSTOL and new
products generally, our financial position and our ability to raise
additional capital to fund operations, if necessary, or to pursue
additional business opportunities, strategic business alliances we may
pursue or the potential acquisition of products or technologies, and our
ability to grow our organization to sustain the commercial launch for
SUSTOL, and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and Heron
takes no obligation to update or revise these statements except as may
be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160128005330/en/
Source: Heron Therapeutics, Inc.
Investor Relations Contact:
Jennifer Capuzelo, 858-703-6063
Associate
Director, Investor Relations
jcapuzelo@herontx.com
Corporate
Contact:
Barry D. Quart, Pharm D., 650-366-2626
Chief
Executive Officer